Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Macrophage ferritin heavy chain/α-synuclein regulatory axis modulates ferroptosis during kidney injury
Tanima Chatterjee, Sarah Machado, Kellen Cowen, Mary E. Miller, Bronte Johnson, Yanfeng Zhang, Laura A. Volpicelli-Daley, Lauren A. Fielding, Rudradip Pattanayak, Frida Rosenblum, László Potor, György Balla, Jozsef Balla, Christian Faul, Abolfazl Zarjou
Tanima Chatterjee, Sarah Machado, Kellen Cowen, Mary E. Miller, Bronte Johnson, Yanfeng Zhang, Laura A. Volpicelli-Daley, Lauren A. Fielding, Rudradip Pattanayak, Frida Rosenblum, László Potor, György Balla, Jozsef Balla, Christian Faul, Abolfazl Zarjou
View: Text | PDF
Research Article Immunology Nephrology

Macrophage ferritin heavy chain/α-synuclein regulatory axis modulates ferroptosis during kidney injury

  • Text
  • PDF
Abstract

Macrophages, endowed with remarkable phenotypic plasticity, are essential for orchestrating injury responses and regulating iron homeostasis. Given the central role of ferritin heavy chain (FtH) as a molecular rheostat linking iron sequestration to redox-dependent signaling, we examined how myeloid FtH governs renal iron trafficking and ensuing oxidative stress pathways during acute kidney injury (AKI). Transcriptome analysis revealed coupling of FtH deficiency in monocytes and macrophages with activation of ferroptosis, a regulated cell death associated with iron accumulation. Moreover, myeloid FtH deletion worsened AKI, increasing leukocyte infiltration and iron deposition, together with ferroptosis-associated gene induction, oxidative stress, and lipid peroxidation. Notably, α-synuclein (SNCA), an iron-binding protein and the main pathological driver of Parkinson’s disease, was robustly induced both by FtH deficiency and following AKI. Mechanistic studies showed that monomeric SNCA exhibits ferrireductase activity, amplifying redox cycling and promoting ferroptotic cell death. Furthermore, SNCA expression was elevated in kidney pathologies characterized by leukocyte expansion in both mouse models and human cohorts, suggesting that inflammatory microenvironments promote SNCA accumulation and redox imbalance. These findings define a macrophage FtH/SNCA regulatory axis as a key driver of ferroptosis in AKI, implicating SNCA as a pathological nexus between iron dyshomeostasis and inflammatory kidney injury.

Authors

Tanima Chatterjee, Sarah Machado, Kellen Cowen, Mary E. Miller, Bronte Johnson, Yanfeng Zhang, Laura A. Volpicelli-Daley, Lauren A. Fielding, Rudradip Pattanayak, Frida Rosenblum, László Potor, György Balla, Jozsef Balla, Christian Faul, Abolfazl Zarjou

×

Figure 4

Myeloid FtH deficiency confers susceptibility to ferroptosis following injury.

Options: View larger image (or click on image) Download as PowerPoint
Myeloid FtH deficiency confers susceptibility to ferroptosis following i...
(A and B) Representative blot showing HNE (A) and ACSL4 (B) protein expression levels in kidney lysates from mice treated with vehicle or AA. (C) Densitometric quantification of HNE expression normalized to GAPDH (vehicle, n = 1 per genotype; AA, n = 5 per genotype). (D) Densitometric quantification of ACSL4 expression normalized to GAPDH (vehicle, n = 1 per genotype; AA, n = 6 per genotype). (E–G) mRNA expression levels of Nrf2 (E), Slc7a11 (F), and Slc40a1 (G) in kidneys at 6 weeks after treatment. Data are normalized to Gapdh and represented as fold versus FtHfl/fl vehicle group (vehicle, n = 6 per genotype; AA, n = 6 per genotype). (H) Whole-kidney lysates, collected at 6 weeks from both genotypes after vehicle or AA treatment, were analyzed to quantify malondialdehyde (MDA) levels as a measure of lipid peroxidation (n = 12 per genotype and treatment condition). (I) Modified Perls Prussian blue staining demonstrating iron deposition in kidneys of FtHfl/fl and FtHΔ/Δ mice at 6 weeks after AA treatment. Scale bars: 200 μm (top), 50 μm (bottom). (J) Representative immunohistochemistry to detect HNE accumulation in both genotypes at 6 weeks after AA administration. Scale bars: 100 μm. *P < 0.05, ***P < 0.001.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts